Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease


Triptolide has been approve effective in animal model.

Full Title of Study: “Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2013

Detailed Description



  • Drug: tripterygium wilfordii
    • TW,60mg/d
  • Drug: Emodin
    • 100mg/d

Arms, Groups and Cohorts

  • Active Comparator: emodin
  • Experimental: Triptolide Woldifii
    • TW60mg/d

Clinical Trial Outcome Measures

Primary Measures

  • MRI calculated kidney volume, eGFR
    • Time Frame: Every 3-6months

Secondary Measures

  • End-stage kidney disease (ESRD)
    • Time Frame: every 2months

Participating in This Clinical Trial

Inclusion Criteria

  • Clinically established ADPKD – eGFR>30ml/min. – Chinese nationality Exclusion Criteria:

  • Uncontrolled infections – Non-ADPKD complications

Gender Eligibility: All

Minimum Age: 15 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Zhi-Hong Liu, M.D.
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Zhi-Hong Liu, M.D., professor – Nanjing University School of Medicine
  • Overall Official(s)
    • Liu Zhihong, Master, Principal Investigator, Research Institute of Nephrology, Jinling Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.